Drug
Casdatifan
Casdatifan: highest development phase Phase 3, developed by Arcus Biosciences. 7 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Arcus Biosciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| Casdatifan NCT07011719 | Phase 3 | Metastatic Clear Cell Renal Cell Carcinoma |
| Casdatifan NCT06919991 | Phase 1 | Healthy Participants |
| casdatifan NCT05117554 | Phase 1 | Healthy Participants |
| Casdatifan NCT07751250 | Phase 1 | Healthy Participants |
| Casdatifan NCT07641881 | Phase 1 | Healthy Participants |
| casdatifan NCT05999513 | Phase 1 | Healthy Participants |
| casdatifan NCT05536141 | Phase 1 | Clear Cell Renal Cell Carcinoma |
Latest
Follow Casdatifan on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.